411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients

por DiPippo, Adam J, Rausch, Caitlin R, Kontoyiannis, Dimitrios P
Publicado 2018

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy

por Spitznogle, Sarah L, Rausch, Caitlin R, Bhatti, Micah M, Shelburne, Samuel A, Aitken, Samuel L
Publicado 2020

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

por Reville, Patrick K., Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, DiNardo, Courtney D., Daver, Naval, Pemmaraju, Naveen, Ohanian, Maro, Alvarado, Yesid, Xiao, Lianchun, Alatrash, Gheath, Loghavi, Sanam, Rausch, Caitlin R., Borthakur, Gautam, Konopleva, Marina, Cortes, Jorge, Kadia, Tapan M.
Publicado 2021

2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Stud...

por Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Kadia, Tapan M, Borthakur, Gautam, Ravandi-Kashani, Farhad, Masarova, Lucia, Konopleva, Marina, Estrov, Zeev, Takahashi, Koichi, Yilmaz, Musa, Rausch, Caitlin R, Marx, Kayleigh, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Publicado 2019

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

por Richard-Carpentier, Guillaume, Rausch, Caitlin R., Sasaki, Koji, Hammond, Danielle, Morita, Kiyomi, Takahashi, Koichi, Tang, Guilin, Kanagal-Shamanna, Rashmi, Bhalla, Kapil, Dinardo, Courtney D., Borthakur, Gautam, Pemmaraju, Naveen, Shpall, Elizabeth J., Alousi, Amin, Daver, Naval G., Garcia-Manero, Guillermo, Konopleva, Marina Y., Ravandi, Farhad, Kantarjian, Hagop M., Kadia, Tapan M.
Publicado 2023

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

por Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., Konopleva, Marina Y.
Publicado 2021

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens

por Maiti, Abhishek, Rausch, Caitlin R., Cortes, Jorge E., Pemmaraju, Naveen, Daver, Naval G., Ravandi, Farhad, Garcia-Manero, Guillermo, Borthakur, Gautam, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Kadia, Tapan M., Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven, Montalban-Bravo, Guillermo, Sasaki, Koji, Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Jabbour, Elias J., Masarova, Lucia, Thompson, Philip A., Wang, Sa, Konoplev, Sergej, Pierce, Sherry A., Ning, Jing, Qiao, Wei, Welch, John S., Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Publicado 2020